Clinical Report: Acoramidis Linked to Lower Mortality Through 54 Months

Overview

Early and continuous acoramidis therapy significantly reduced all-cause and cardiovascular mortality among patients with transthyretin amyloid cardiomyopathy over 54 months. The findings underscore the importance of initiating treatment early to optimize patient outcomes.

Background

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition that can lead to severe heart failure and increased mortality. Effective management strategies are crucial for improving patient survival and quality of life. Acoramidis, a transthyretin stabilizer, has emerged as a promising therapeutic option, warranting investigation into its long-term effects.

Data Highlights

Key Findings

• Continuous acoramidis treatment was associated with a 45% lower risk of all-cause mortality compared to delayed initiation.
• Patients receiving continuous therapy had a 49% lower risk of cardiovascular mortality.
• First cardiovascular hospitalization occurred in 35% of patients on continuous therapy versus 57% in the delayed initiation group.
• Continuous therapy resulted in smaller increases in N-terminal pro–B-type natriuretic peptide levels (40% vs 149%).
• Functional capacity, measured by the Kansas City Cardiomyopathy Questionnaire, declined less in the continuous therapy group (5% vs 16%).

Clinical Implications

The findings highlight the critical role of early and continuous treatment with acoramidis in managing ATTR-CM. Clinicians should consider initiating therapy as soon as the diagnosis is confirmed to maximize survival benefits and improve patient outcomes.

Conclusion

Acoramidis demonstrates significant long-term benefits in reducing mortality and hospitalizations in patients with transthyretin amyloid cardiomyopathy. Early intervention is essential for optimizing treatment efficacy.

Related Resources & Content

1. Soman P, et al., JAMA Cardiology, 2026 -- Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial
2. Drugs - Real World Outcomes — Association of Anticholinergic Medication Use at Hospital Admission with Mortality Rates in Elderly Patients: A Nationwide Cohort Study from Denmark
3. the asco post — Early-Onset ICI-Related Myocarditis Linked to Increased Mortality
4. The Journal of Clinical Endocrinology & Metabolism — The Relationship Between Inflammation and Mortality Risk in Type 2 Diabetes: Insights into the Connection with Tryptophan Metabolism
5. The Journal of Clinical Endocrinology & Metabolism — Decline in Glomerular Filtration Rate as a Predictor of Overall Mortality and Its Mediating Role in Tryptophan Metabolism's Impact on Mortality Risk in Type 2 Diabetes
6. Multimodality Imaging for ATTR Amyloid Cardiomyopathy: Key Points - American College of Cardiology
7. Tafamidis in Transthyretin Cardiomyopathy Clinical Trial - American College of Cardiology
8. Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial | Trials | JAMA Cardiology | JAMA Network